Nemluvio (Nemolizumab-Ilto) for Prurigo Nodularis

Overview
Nemluvio is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with prurigo nodularis, a chronic skin condition characterized by intensely itchy nodules. This medication is prescribed to those who require targeted treatment to manage severe symptoms of prurigo nodularis. Nemluvio is also known by its drug name, nemolizumab-ilto.

Nemluvio is a biologic drug classified as an interleukin (IL)-31 receptor antagonist. It works by blocking the activity of IL-31 (a protein in the immune system), which is believed to play a key role in the development of itching and inflammation in prurigo nodularis.

How do I take it?
Prescribing information states that Nemluvio is administered by subcutaneous (under the skin) injection in the form of a single-dose, prefilled dual-chamber pen. Dosing sizes depend on a person’s weight. After an initial dose, a person receives a new dose every four weeks. The medication must be reconstituted (mixed with a liquid) before administration. Nemluvio should be administered exactly as prescribed by a health care provider.

Side effects
Common side effects of Nemluvio include headache, atopic dermatitis (a type of eczema), eczema, and eczema nummular (a type of eczema with coin-shaped spots).

Rare but serious side effects may include hypersensitivity reactions (severe allergic reactions).

For more information about this treatment, visit:

Nemluvio (Nemolizumab-Ilto) for Injection, for Subcutaneous Use — U.S. Food & Drug Administration

Nemluvio — Drugs.com